Publications and Supporting Literature
Disc Publications
ASH 2020
DISC-0974, a novel, first-in-class, anti-hemojuvelin monoclonal antibody decreases hepcidin and increases transferrin saturation in a non-human primate model of cytokine (IL-6) induced…
read more
Porphyria Symposium 2021
Proof of Mechanism Studies with Bitopertin, a Selective Glycine Transporter 1 Inhibitor Under Development for the Treatment of Erythropoietic Protoporphyria (EPP) and…
read more
EHA 2021
Disc-B, a selective matriptase-2 inhibitor, elicited robust increase in hepcidin-25 and reduction in serum iron in cynomolgus moneys
read more
ASH 2021
Proof of Mechanism Studies with Bitopertin, a Selective Glycine Transporter 1 Inhibitor Under Development for the Treatment of Erythropoietic Protoporphyria (EPP) and…
read more
Supporting Literature
Mat2
Hepcidin agonists as therapeutic tools
Casu, C., Nemeth, E., & Rivella, S. (2018). Hepcidin agonists as therapeutic tools. Blood, 131(16), 1790–1794.
DISC-0974
Anemia of inflammation
Weiss, G., Ganz, T., & Goodnough, L. T. (2019). Anemia of inflammation. Blood, 133(1), 40–50.
DISC-0974
Hepcidin-mediated hypoferremic response to acute inflammation requires a threshold of Bmp6/Hjv/Smadsignaling
Fillebeen, C., Wilkinson, N., Charlebois, E., Katsarou, A., Wagner, J., & Pantopoulos, K. (2018). Hepcidin-mediated hypoferremic response to acute inflammation requires a threshold of Bmp6/Hjv/Smad signaling. Blood, 132(17), 1829–1841.
DISC-0974
Iron Balance and the Role of Hepcidin in Chronic Kidney Disease
Ganz, T., & Nemeth, E. (2016). Iron Balance and the Role of Hepcidin in Chronic Kidney Disease. Seminars in Nephrology, 36(2), 87–93.
DISC-0974
Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies
Naymagon, L., & Mascarenhas, J. (2017). Myelofibrosis-Related Anemia. HemaSphere, 1(1), e1.
DISC-0974
The Relation of Hepcidin to Iron Disorders, Inflammation and Hemoglobin in Chronic Kidney Disease
Mercadel, L., Metzger, M., Haymann, J. P., Thervet, E., Boffa, J.-J., Flamant, M., Vrtovsnik, F., Houillier, P., Froissart, M., & Stengel, B. (2014). The Relation of Hepcidin to Iron Disorders, Inflammation and Hemoglobin in Chronic Kidney Disease. PLoS ONE, 9(6), e99781.
DISC-0974
Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis
Pardanani, A., Mengistu, B., Finke, C., Lasho, T. L., & Tefferi, A. (2012). Associations and Prognostic Interactions Between Circulating Levels of Hepcidin, Ferritin, and Inflammatory Cytokines in Primary Myelofibrosis. Blood, 120(21), 2831–2831.
DISC-0974
Anti-repulsive Guidance Molecule C (RGMc) Antibodies Increases Serum Ironin Rats and Cynomolgus Monkeys by Hepcidin Downregulation
Böser, P., Seemann, D., Liguori, M. J., Fan, L., Huang, L., Hafner, M., Popp, A., & Mueller, B. K. (2015). Anti-repulsive Guidance Molecule C (RGMc) Antibodies Increases Serum Iron in Rats and Cynomolgus Monkeys by Hepcidin Downregulation. The AAPS Journal, 17(4), 930–938.
DISC-0974
Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels
Citation: Kovac, S., Boser, P., Cui, Y., Ferring-Appel, D., Casarrubea, D., Huang, L., Fung, E., Popp, A., Mueller, B. K., & Hentze, M. W. (2016). Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels. Haematologica, 101(5), e173–e176.
Bitopertin
Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria
Balwani, M., Naik, H., Anderson, K. E., Bissell, D. M., Bloomer, J., Bonkovsky, H. L., Phillips, J. D., Overbey, J. R., Wang, B., Singal, A. K., Liu, L. U., & Desnick, R. J. (2017). Clinical, biochemical, and genetic characterization of North American patients with erythropoietic protoporphyria and X-linked protoporphyria. JAMA Dermatology, 153(8), 789.
Bitopertin
Evidence in the UK Biobank for the underdiagnosis of erythropoietic protoporphyria
Dickey, A. K., Quick, C., Ducamp, S., Zhu, Z., Feng, Y.-C. A., Naik, H., Balwani, M., Anderson, K. E., Lin, X., Phillips, J. E., Rebeiz, L., Bonkovsky, H. L., McGuire, B. M., Wang, B., Chasman, D. I., Smoller, J. W., Fleming, M. D., & Christiani, D. C. (2021). Evidence in the UK Biobank for the underdiagnosis of erythropoietic protoporphyria. Genetics in Medicine, 23(1), 140–148.
Bitopertin
Extracellular glycine is necessary for optimal hemoglobinization of erythroid cells
Garcia-Santos, D., Schranzhofer, M., Bergeron, R., Sheftel, A. D., & Ponka, P. (2017). Extracellular glycine is necessary for optimal hemoglobinization of erythroid cells. Haematologica, 102(8), 1314–1323.
Bitopertin
Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient
Pinard, E., Borroni, E., Koerner, A., Umbricht, D., & Alberati, D. (2018). Glycine transporter type I (glyt1) inhibitor, Bitopertin: A journey from lab to patient. CHIMIA, 72(7-8), 477.
Bitopertin
Effects of GlyT1 inhibition on erythropoiesis and iron homeostasis in rats
Winter, M., Funk, J., Körner, A., Alberati, D., Christen, F., Schmitt, G., Altmann, B., Pospischil, A., & Singer, T. (2016). Effects of GLYT1 inhibition on erythropoiesis and iron homeostasis in rats. Experimental Hematology, 44(10).
Bitopertin
Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP
Linenberger, M., & Fertrin, K. Y. Hematology. American Society of Hematology. Education Program, 2020(1), 400–410.
Bitopertin
Protoporphyrin IX in the skin measured noninvasively predicts photosensitivity in patients with erythropoietic protoporphyria
Heerfordt, I. M., & Wulf, H. C. (2016). The British journal of dermatology, 175(6), 1284–1289.
Bitopertin
Inactivation of protoporphyrin IX in erythrocytes in patients with erythropoietic protoporphyria: A new treatment modality
Wulf, H. C., Nissen, C. V., & Philipsen, P. A. (2020). Photodiagnosis and photodynamic therapy, 29, 101582.